TILT Biotherapeutics Oy is led by a highly experienced team with decades of expertise in early-stage cancer therapeutics research and development. Based in Finland, the company also operates a wholly owned U.S. subsidiary and has established a dedicated new spin-out entity TiltBio Inc to drive the later-stage development of its lead asset, TILT-123.
TiltBio Inc
The U.S. team contributes complimentary industry expertise from both Europe and the United States to drive the progression of the lead asset into late-stage development.
Board of Directors
The Board includes leading authorities and serial entrepreneurs in the life sciences, legal, financial, and pharmaceutical fields. The board is chaired by Arto Linnervuo.
